Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 11/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.66 |
| ▸ | USP2 | O75604 | 7/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.65 |
| ▸ | TSHR | P16473 | 8/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520036 | 0.84 | ADORA2A (0.72) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL13966174 | 0.82 | ADORA2A (0.83) | ADORA2AADORA1 | |
| SCHEMBL4526407 | 0.81 | ADORA2A (0.60) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL13966250 | 0.80 | ADORA2A (0.92) | ADORA2AADORA1 | |
| SCHEMBL4531259 | 0.79 | ADORA2A (0.91) | ADORA2AADORA1 | |
| SCHEMBL4520917 | 0.79 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL13966164 | 0.78 | ADORA2A (0.71) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL13966151 | 0.76 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL13966138 | 0.76 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL4532246 | 0.76 | ADORA2A (0.64) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | ADORA2A, P2RX6, P2RX5 | CYP1A2 1602/4885CYP3A4 3251/4885CYP2C19 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.